OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $904,000 Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 2.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,257 shares of the company’s stock after selling 426 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Disc Medicine were worth $904,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IRON. Barclays PLC raised its position in shares of Disc Medicine by 123.7% in the 3rd quarter. Barclays PLC now owns 40,145 shares of the company’s stock valued at $1,972,000 after acquiring an additional 22,202 shares during the period. JPMorgan Chase & Co. increased its stake in Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after purchasing an additional 2,257 shares in the last quarter. SG Americas Securities LLC increased its stake in Disc Medicine by 66.0% in the fourth quarter. SG Americas Securities LLC now owns 8,076 shares of the company’s stock valued at $512,000 after purchasing an additional 3,212 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock worth $400,000 after purchasing an additional 593 shares during the period. Finally, Bleakley Financial Group LLC bought a new position in shares of Disc Medicine during the fourth quarter worth $486,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a report on Friday, March 7th. Scotiabank raised their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. BMO Capital Markets lifted their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a report on Monday. Finally, TD Cowen initiated coverage on Disc Medicine in a research note on Thursday, February 27th. They set a “buy” rating for the company. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Buy” and an average price target of $98.80.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $46.35 on Wednesday. The stock has a 50-day simple moving average of $46.54 and a 200 day simple moving average of $54.93. Disc Medicine, Inc. has a 52-week low of $30.65 and a 52-week high of $68.73. The company has a market cap of $1.60 billion, a PE ratio of -11.65 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.03). On average, research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Activity at Disc Medicine

In related news, insider Pamela Stephenson sold 3,137 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the completion of the transaction, the insider now directly owns 69,529 shares of the company’s stock, valued at approximately $3,794,892.82. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $87,873.80. Following the transaction, the chief operating officer now owns 40,555 shares in the company, valued at approximately $2,213,491.90. The trade was a 3.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 356,290 shares of company stock valued at $19,336,901. Corporate insiders own 4.24% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.